Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Livzon Pharmaceutical Group ( (HK:1513) ) just unveiled an update.
Livzon Pharmaceutical Group has updated its registered capital to RMB887,907,171 after changes in share capital arising from the exercise of share incentives and the cancellation of repurchased shares, resulting in 887,907,171 ordinary shares split between domestic and overseas listings. This recalibration aligns the formal capital base with the company’s current share count and supports accurate regulatory and industrial and commercial registration.
The company also plans to adjust the size of its 11th Board of Directors to a flexible range of 9–11 members, while maintaining at least one-third independent non-executive directors to meet Chinese and Hong Kong listing governance requirements. Corresponding amendments to the Articles of Association are being made to reflect both the new registered capital and the revised board structure, aiming to enhance operational efficiency while preserving a compliant and robust governance framework for stakeholders.
The most recent analyst rating on (HK:1513) stock is a Sell with a HK$22.99 price target. To see the full list of analyst forecasts on Livzon Pharmaceutical Group stock, see the HK:1513 Stock Forecast page.
More about Livzon Pharmaceutical Group
Livzon Pharmaceutical Group Inc. is a China-based pharmaceutical company engaged in the research, development, production and sale of medicines. The group focuses on both domestic-listed and overseas-listed shares, reflecting a dual-market capital structure that supports its operations and corporate governance in the broader healthcare and life sciences sector.
Average Trading Volume: 774,806
Technical Sentiment Signal: Hold
Current Market Cap: HK$29.76B
For detailed information about 1513 stock, go to TipRanks’ Stock Analysis page.